HMGA2 and pancreatic neoplasm: Despite Hmga2 having no effect in gemcitabine-treated mouse models of pancreatic cancer, it remains possible that HMGA2 may still be a determinant of therapy sensitivity in human PDAC or of response to other chemotherapies.